Message #19 From:
NewsBot Date: November 20, 2006 10:09:00 AM
APPA News A.P. Pharma Names New Vice President of Clinical Development
REDWOOD CITY, Calif.--(BUSINESS WIRE)--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical
company, today announced that Anastassios D. Retzios, Ph.D. has joined
the Company in the newly created position of Vice President of Clinical
Development, reporting to Gregory Turnbull, the Company’s
Chief Executive Officer. Dr. Retzios has more than 18 years of
experience in a wide range of clinical and regulatory matters, most
recently as Director of Global Clinical Research and Development at
Baxter BioScience. Previously he served in senior clinical positions at
Questcor Pharmaceuticals and Alpha Therapeutic Corporation.
In commenting on the appointment of Dr. Retzios, Mr. Turnbull said “we
are delighted to have Anastassios on our team. The experience and
expertise he brings to us will be of paramount importance as we pursue
our pivotal phase 3 clinical trial for APF530.”
APF530 is the Company’s lead compound for the
prevention of both acute and delayed chemotherapy-induced nausea and
vomiting.
About A.P. Pharma
A.P. Pharma is a specialty pharmaceutical company focused on the
development of ethical (prescription) pharmaceuticals utilizing its
proprietary polymer-based drug delivery systems. The Company’s
primary focus is the development and commercialization of its
bioerodible injectable and implantable systems under the trade name
Biochronomer™. Initial target areas of
application for the Company’s drug delivery
technology include anti-nausea, pain management, anti-inflammation and
DNA/RNAI applications. For further information visit the Company’s
web site at www.appharma.com.
